Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease

Nature Clinical Practice Nephrology

Volumn 4, Issue 7, 2008, Pages 364-365

  Coyne, Daniel W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; CALCIUM SENSING RECEPTOR; CINACALCET; PARATHYROID HORMONE; VITAMIN D; CALCIUM ION; PHOSPHORUS; PLACEBO;

BRAIN CALCIFICATION; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG SAFETY; HUMAN; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY CALCIFICATION; NEPHROLITHIASIS; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; SECONDARY HYPERPARATHYROIDISM; SHORT SURVEY; VITAMIN D DEFICIENCY; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; MORTALITY; PHOSPHATE BLOOD LEVEL; RISK REDUCTION;

ANIMALS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 46249132281     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0821     Document Type: Short Survey

References (13)

1. Slatopolsky E et al. (1999) Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 73: S14-S19
2. Levin A et al. (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71: 31-38
3. Wolf M et al. (2007) Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72: 1004-1013
4. Coyne D et al. (2006) Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 47: 263-276
5. Coburn JW et al. (2004) Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 43: 877-890
6. Goodman WG et al. (1998) Calcium-sensing by parathyroid glands in secondary hyperparathyroidism. J Clin Endocrinol Metab 83: 2765-2772
7. Delmez JA et al. (1989) Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D: a role for increased sensitivity to calcium. J Clin Invest 83: 1349-1355
8. Gunn IR and Gaffney D (2004) Clinical and laboratory features of calcium-sensing receptor disorders: a systematic review. Ann Clin Biochem 41: 441-458
9. Moe SM et al. (2005) Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 20: 2186-2193
10. Charytan C et al. (2005) Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 46: 58-67
11. US FDA (online 5 July 2004) Sensipar (Cinacalcet HCI) Tablets Approval Application No.: 021688 [http://www.fda.gov/cder/foi/nda/2004/21-688_Sensipar. htm] (accessed 24 January 2008)
12. Health Canada (online 19 June 2007) Sensipar® no longer indicated for chronic kidney disease patients (stages 3 and 4) not receiving dialysis [http://www.hcsc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2007/ sensipar_hpc-cps_e.html] (accessed 22 January 2008)
13. Ba J and Friedman PA (2004) Calcium-sensing receptor regulation of renal mineral ion transport. Cell Calcium 35: 229-237